TIDMBYOT

Byotrol PLC

14 November 2023

Byotrol Plc

("Byotrol" or the "Company")

Launch of PROCESSUS(R) Instrument Decontamination System

Leading antimicrobial technology company Byotrol plc (AIM:BYOT) has today announced the launch of PROCESSUS(R), a 360-degree instrument decontamination system, intended for the simple and effective reprocessing of instruments and specialist equipment, in both animal and human healthcare organisations.

PROCESSUS(R) is the third launch of Byotrol's next-generation surface disinfectant technology, which was first introduced in November 2022, under Byotrol's market-leading ANIGENE brand and subsequently launched under the CHEMGENE brand earlier this year.

Instrument decontamination refers to the process of making instruments and equipment safe for use. This can be achieved by removing, deactivating, or destroying contaminants, which can range from organic dirt and debris to harmful pathogens, like viruses, bacteria, and fungi. While the pathogenic threats to good patient care may differ slightly, the fundamental principles of effective instrument decontamination remain the same in both human and animal health environments.

The new PROCESSUS(R) brand debuts at the London Vet Show on the 16(th) November, where Byotrol will be demonstrating the ease-of-use and flexibility of the PROCESSUS(R) product range to animal health professionals from its key commercial partners in veterinary, welfare and rehoming charities, and zoos and wildlife organisations.

The PROCESSUS(R) Instrument Decontamination System incorporates enzymatic cleaners, which are designed to remove organic matter prior to disinfection, using a triple enzyme formulation which protects the integrity of instruments. Post-cleaning, PROCESSUS(R) Instrument Disinfectant kills bacteria, yeasts, fungi, and viruses, including multi-drug resistant pathogens as well as denaturing DNA / RNA.

Central to all Byotrol products, the PROCESSUS(R) Instrument Decontamination System is supported by rigorous testing to the latest European efficacy test methodology, specifically those required for instrument submersion. The formulation is compatible with a wide range of equipment including thermos-sensitive and fine lumened devices, nasal / fibre-optic scopes, diagnostic and orthopedic equipment, and surgical and endontic instruments.

David Traynor, Interim CEO of Byotrol states:

"The launch of Byotrol's new PROCESSUS(R) Instrument Decontamination System demonstrates another step forward in our plans to future-proof our portfolio for EU and UK BPR regulatory approvals. It is the third in a series of strategic portfolio updates, which strengthens our offering in both animal health and human health markets."

For detailed information about the forthcoming PROCESSUS(R) Instrument Decontamination range and supporting product documentation please visit our commercial website, www.byotrol.com and follow the company on LinkedIn.

For further information contact:

 
 Byotrol Plc 
 Dr Trevor Francis, Non- Executive Chairman                   +44 (0)1925 742 000 
 David Traynor, Interim Chief Executive             investorrelations@byotrol.com 
  Officer 
  Chris Sedwell, Chief Financial Officer 
 
 Cavendish Capital Markets Limited (Nominated 
  Adviser and Broker)                                         +44 (0)20 7220 0500 
 Geoff Nash / George Dollemore - Corporate 
  Finance 
 Nigel Birks / Harriet Ward - ECM 
 
 Flagstaff Strategic and Investor Communications              +44 (0)20 7129 1474 
 Tim Thompson/Andrea Seymour/Fergus Mellon             byotrol@flagstaffcomms.com

Notes to editors

Byotrol plc (BYOT.L), quoted on AIM, is a specialist infection prevention and control company, operating globally in animal health, human health, consumer products and facilities management sectors. Byotrol develops and commercialises innovative biocidal technologies and brands which provide targeted protection against harmful pathogens.

For more information about Byotrol plc please visit byotrolplc.com and follow the company on LinkedIn .

For information on Byotrol products and customers please visit byotrol.com

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NRAEAEFLFFSDFEA

(END) Dow Jones Newswires

November 14, 2023 02:00 ET (07:00 GMT)

Byotrol (LSE:BYOT)
Historical Stock Chart
From Jan 2025 to Feb 2025 Click Here for more Byotrol Charts.
Byotrol (LSE:BYOT)
Historical Stock Chart
From Feb 2024 to Feb 2025 Click Here for more Byotrol Charts.